Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070611 | 0.88 | PPARG (0.38) | PTGESPPARGPPARAALOX5SMN1; SMN2 | |
| SCHEMBL7067720 | 0.87 | PPARA (0.50) | PPARGPPARAPPARD | |
| SCHEMBL7066480 | 0.82 | LDHA (0.42) | SMN1; SMN2MAPTTHRBMAOBKDM4E | |
| SCHEMBL7069475 | 0.82 | PPARG (0.36) | PTGESPPARGPPARAALOX5SMN1; SMN2 | |
| SCHEMBL7066025 | 0.82 | MAPT (0.40) | SMN1; SMN2MAPTTHRBMAOBKDM4E | |
| SCHEMBL7072705 | 0.82 | KDM4E (0.41) | SMN1; SMN2MAPTTHRBKMT2AKDM4E | |
| SCHEMBL7069531 | 0.81 | LDHA (0.40) | PPARGPPARASMN1; SMN2MAPTTHRB | |
| SCHEMBL7067668 | 0.80 | PPARA (0.53) | PPARGPPARAPPARD | |
| SCHEMBL7066505 | 0.80 | PPARG (0.53) | PPARGPPARA | |
| SCHEMBL7071902 | 0.79 | PPARG (0.43) | PPARGPPARASMN1; SMN2MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | PTGES 609/4885PPARG 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.